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Alopecia areata (AA) is an autoimmune condition characterized by T cell–
mediated attack of the hair follicle. The inciting antigenic stimulus is unknown.
A dense perbulbar lymphocytic infiltrate and reproducible immunologic abnorm-
alities are hallmark features of the condition. The cellular infiltrate primarily
consists of activated T lymphocytes and antigen-presenting Langerhans cells. The
xenon chloride excimer laser emits its total energy at the wavelength of 308 nm
and therefore is regarded as a ‘‘super-narrowband’’ UVB light source. Excimer
laser treatment is highly effective in psoriasis, another T cell–mediated disorder
that shares many immunologic features with AA. The excimer laser is superior in
inducing T cell apoptosis in vitro compared with narrowband UVB, with paralleled
improved clinical efficacy. The excimer laser has been used successfully in patients
with AA. In this context, evaluation of the potential benefit of 308-nm excimer
laser therapy in the treatment of AA is clinically warranted. Herein, the use of a
common treatment protocol with a specifically designed module to study the
outcome of excimer laser treatment on moderate-to-severe scalp AA in adults is
described.
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Introduction
Alopecia areata (AA) is an autoimmune
condition characterized by T cell–
mediated attack on the hair follicle
(Madani and Shapiro, 2000). The
inciting antigenic stimulus is unknown.
A dense peribulbar lymphocytic infiltrate
and reproducible immunologic abnor-
malities are hallmark features of the
condition. T lymphocytes have a critical
role in the pathogenesis of disease.
Gilhar et al. (1998) have reported that
AA can be reversed in human scalp skin
specimens of AA when transplanted to
severe-combined immunodeficiency
mice. The observance of hair regrowth
in those with AA, who are treated with
cyclosporine, a known inhibitor of T cell
function, further confirms the central
role of T lymphocytes in the develop-
ment of disease (Miller et al., 1993;
Wingren et al., 1995; Shapiro et al.,
1997; Gilhar et al., 2012).
Several AA treatments utilize topical
immunomodulation to induce an inter-
mittent allergic contact dermatitis in
affected areas (Happle et al., 1983;
van der Steen et al., 1992). UV
radiation in the form of UVA or UVB
has been used to induce an immune
response in AA, with the suspected
mechanism of clinical improvement
surrounding UV-induced apoptosis of
pathogenic T cells. (Gundogan et al.,
2004) Narrowband UVB is a more
potent inducer of T cell apoptosis, and
therefore demonstrates clinical efficacy
over broadband UVB (Coven et al.,
1997; Ozawa et al., 1999).
The xenon chloride excimer laser
emits its total energy at a wavelength
of 308 nm and therefore is regarded as a
‘‘super-narrowband’’ UVB light source.
In contrast, narrowband UVB primarily
emits polychromatic, non-coherent light
in the 311–313 nm wavelength range.
Excimer laser treatment is highly effec-
tive in psoriasis, another T cell–
mediated disorder that shares many
immunologic features with AA (Bo´nis
et al., 1997; Asawanonda et al., 2000;
Feldman et al., 2002). Although the
exact mechanism by which the excimer
laser clears psoriasis is not known, it is
postulated that an increased induction
of T cell apoptosis leads to a decrease in
T-lymphocyte proliferation (Passeron
and Ortonne, 2006). With decreased T
cell depletion and decreased antigen
presentation, the excimer laser may
stabilize diseases like psoriasis and AA
(Park et al., 2012). In vitiligo, there may
be a more complicated process with
stimulation of melanocyte migration
and proliferation in the hair follicles
along with the laser-induced immuno-
suppressive effect. It is known that the
308 nm wavelength is more efficient at
inducing DNA lesions on lymphocytes
than typical narrowband UVB (Novak
et al., 2002). The excimer laser has been
used successfully in patients with AA
(Gundogan et al., 2004; Zakaria et al.,
2004; Raulin et al., 2005). In one series
of 11 children with recalcitrant AA of
the scalp, regrowth was noted in 60% of
patches treated with the excimer laser
for 12 weeks versus no regrowth in
untreated control patches (Al-Mutari,
2009). A larger study of 18 children
and adults with 42 recalcitrant alopecic
patches demonstrated regrowth in 17
(42%) of patches after 12 weeks, with
13 of 18 scalp lesions showing complete
regrowth (Al-Mutari, 2007). In addition
to the immune effects, the direct effect
of excimer photons on the melanocytes
may also have a role in the successful
treatment of AA. The excimer laser
technique has not yet been explored in
large, multicenter trials.
All available treatments for AA have
limited benefit, and none are curative or
Food and Drug Administration-approved.
As approximately 2% of the world
population has a lifetime risk of devel-
oping AA (Safavi, 1992; Safavi et al.,
1995), and the effect of disease on
the psychosocial well-being of those
affected can be devastating, the need
for more effective, safe treatments is of
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utmost importance. In this context,
evaluation of the potential therapeutic
benefit of 308-nm excimer laser therapy
in the treatment of AA is clinically
warranted. This paper outlines the use
of a component module of a common
protocol to plan and execute a treatment
study for AA.
Study description
This study protocol is a module of the
newly designed common protocol for
AA. The common protocol has been
designed by a working group of the
National Alopecia Areata Foundation
to promote treatment studies for AA. It
is a versatile protocol that can be shared
with any investigator who is interested
in initiating a treatment study for AA
scalp disease. By simply following a
common set of inclusion/exclusion cri-
teria and study visits, investigators will
have an opportunity to amend the pro-
tocol for their interests without having to
design a new protocol from inception.
Changes can be made to any compo-
nent of the study, and for the module
discussed, utilizing the excimer laser,
statistics and study visits were altered for
best clinical study practices.
The excimer module of the common
study has been planned to investigate, in
a prospective manner, the safety and
efficacy of the 308-nm excimer laser in
the treatment of subjects 18 years or
older with moderate-to-severe AA of the
scalp. Secondary objectives for this
study include: (1) documenting the dur-
ability of the response of the excimer
laser treatment on AA over a 6-week
post-treatment observation period and
(2) qualitatively assessing the subject’s
perception of their scalp disease with
treatment.
This module is designed as a double-
blind, randomized, controlled, multi-
center, investigator-initiated study to
examine the safety and efficacy of
308-nm excimer laser treatment in a
voluntary population of subjects with
chronic, moderate-to-severe scalp AA.
A total of 78 eligible subjects will be
enrolled in the study at five different
sites in the United States. Study enrol-
lees will be randomized to two treat-
ment groups. Group 1 (excimer laser
group) will undergo two times weekly
treatments with the excimer laser to
affected areas on the scalp, with at least
one untreated patch (6.13.1 cm2) ser-
ving as a control. Group 2 (control
group) will receive non-active treatment
with a sham device. All study team
members and subjects will be blinded
based on which transmission tip (sham
vs. active) is used. Treatment or non-
active treatment will occur for 24
weeks, during which the safety and
efficacy will be assessed at visits 6, 12,
18, 24, 30, 36, 42, 48, 49, and 50.
The protocol of the study includes AA
history, investigator, and patient assess-
ment of disease activity, photographs,
treatment, and adverse event monitor-
ing. (Table 1) The active visits will be
followed by a 6-week post-treatment
period during which the durability of
effect in treatment responders will be
assessed.
Discussion
The development of the common treat-
ment protocol to streamline AA studies
has been a valuable tool in the arma-
mentarium for National Alopecia Areata
Foundation and investigators interested
in moving the science of AA forward.
The working group for the development
of both the common and excimer mod-
ule of the protocol has attempted to
address any permutation of a treatment
study that can be constructed for AA.
The specifics necessitated by a light
therapy study have been included in
this module with detailed and annotated
instructions for each data point to be
collected. Going forward, it will be
imperative to standardize therapy for
patients suffering with AA and this will
be one of the first attempts at developing
a set of scientific procedures that can
address treating this devastating disease.
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